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Abstract
Early signs and symptoms of autoimmune bullous diseases such as mucous membrane 
pemphigoid (MMP) or pemphigus vulgaris (PV) develop in the oral cavity in almost 
all cases. Desquamative gingivitis (DG) is a clinical manifestation common to several 
diseases or disorders and is frequently associated with autoimmune bullous diseases. 
This is a retrospective study of 37 patients with MMP (24 cases) or PV (13 cases) includ-
ing 10 males and 27 females with a mean age of 58.4 years. The study indicates that DG 
is an early sign of autoimmune bullous diseases such as MMP or PV. About 70.3% of the 
oral lesions were confined only to the gingiva, and DG was the only manifestation of the 
diseases. Since some lesions remain limited to the oral cavity for a long period of time, 
patients diagnosed with MMP or PV should be closely followed because they must be 
immediately referred to other experts when they develop lesions on parts of their body 
other than the oral cavity. The oral healthcare provider should collaborate with other 
healthcare experts including dermatologists, ophthalmologists, and otolaryngologists to 
evaluate and manage patients with autoimmune bullous diseases in the oral cavity.
Keywords: gingival diseases/pemphigus/pemphigoid, benign mucous membrane/
autoimmune diseases/mouth diseases
1. Introduction
Early signs and symptoms of autoimmune bullous diseases such as mucous membrane pem-
phigoid (MMP) or pemphigus vulgaris (PV) develop in the oral cavity in almost all cases. MMP 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
is the most commonly recognized, followed by PV [1]. MMP is one of a group of autoimmune, 
subepithelial blistering diseases that predominantly affect the mucous membranes. MMP is 
considered to be a disease phenotype related to one or more different anti-basement membrane 
zone (BMZ) autoantibodies. Various components in the hemidesmosomes have been recog-
nized as the target antigens of MMP, including bullous pemphigoid antigen 2 (BP180), bullous 
pemphigoid antigen 1 (BP230), laminin 332, type VII collagen, and β4 or α6 integrin subunits 
[2–5]. Most MMP patients are in the fifth or sixth decade of life, and the majority of them are 
women [6–8]. Oral lesions are observed in almost all cases, and the primary lesion often appears 
in the oral cavity [6–10]. PV is an autoimmune bullous disease characterized by acantholysis 
and suprabasilar separation in the epithelium of skin and/or mucous membranes. The main 
target antigen of PV is desmoglein (Dsg) 3, which is a constituent of desmosomes on the kerati-
nocyte [11, 12]. Almost all PV patients with lesions limited to the oral mucosa have circulating 
autoantibodies to Dsg3 [12–15]. PV patients with lesions in the oral mucosa and skin also have 
Dsg1 autoantibodies, the main antigen of pemphigus foliaceus [12, 14, 15]. PV can develop at 
any age, but is most commonly observed in middle-aged and elderly individuals [16–19]. Early 
signs and symptoms of PV develop in the oral cavity in about 80% of patients [19].
Since patients with MMP or PV frequently experience only oral symptoms of pain and dis-
comfort, they often visit the dentist or periodontist before other health care workers [20–22]. 
Desquamative gingivitis (DG) is a condition characterized by painful erythematous gingiva 
not resulting from dental plaque, sloughing of gingival tissues, erosions and ulcerations of the 
gingival epithelium and bulla formation on the gingiva [23–26]. It is a clinical manifestation 
common to several diseases or disorders [23–26]. Most DG patients are caused by mucocu-
taneous diseases. The differential diagnoses include oral lichen planus, MMP, and PV [24]. 
MMP is responsible for 35–48% and PV for 3–15% of DG [26]. Contact allergic reactions to 
various oral hygiene products, dental materials, or food flavoring and preservatives have 
also been reported in the differential diagnosis of DG [23, 24]. Gingival desquamation is a 
prominent clinical feature, and Nikolsky’s sign often shows a positive reaction in DG caused 
by autoimmune bullous diseases [21]. This sign involves the application of a firm sliding or 
rubbing force on normal-appearing gingiva, inducing epithelial desquamation [21, 27].
Although an accurate diagnosis of oral mucosal disease or disorder causing DG is required 
to provide proper treatment, it is almost impossible to do so based solely on clinical appear-
ance. Therefore, histopathological examination and direct immunofluorescence (DIF) testing 
are often required to establish the final diagnosis [24]. The specific disease or disorder causing 
DG, the severity of the DG lesions, the presence or absence of extraoral lesions, and the medi-
cal history of the patient are the key factors in determining the selection of a topical or sys-
temic treatment [10, 23, 24]. In some patients, DG can be successfully managed with moderate 
to very high-potency topical corticosteroids combined with effective plaque control. Patients 
with severe and/or multiple oral lesions, or recalcitrant lesions, may need aggressive systemic 
treatment. The presence of extraoral lesions also may require systemic treatment for effective 
management. Although scarring with MMP is rarely a feature of the oral mucosa, conjuncti-
val scarring may lead to blindness if not treated aggressively [28, 29]. Airway obstruction due 
to laryngeal scarring is a rare condition, but it may occasionally be a fatal complication [30, 
31]. PV is a life-threatening condition if left untreated [32], so it is important to diagnose and 
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treat it in its early stages. This study describes in detail the clinical and diagnostic findings of 
MMP or PV as a common oral manifestation of autoimmune bullous diseases.
2. Materials and methods
This is a retrospective study of 37 patients with MMP (24 cases) or PV (13 cases) who were 
seen by the authors at Nihon University, School of Dentistry at Matsudo between 2001 and 
2017. Patients participating in the study included 10 males and 27 females, aged 24–83 years, 
with a mean age of 58.4 years. The medical records included information on each patient’s 
clinical features, intraoral site involvement, presence or absence of extraoral lesions, dura-
tion from the onset of symptoms until presentation for diagnosis, and diagnostic information 
provided to the patient. A biopsy was obtained that included perilesional tissue and was then 
submitted for routine histopathology and DIF study for each of the 37 patients. DIF study 
was performed using conjugates for immunoglobulin (Ig) G, IgA, IgM, complement C3, and 
fibrinogen. Patients were diagnosed with MMP or PV through clinical examination supported 
by histologic diagnosis and DIF testing [24, 25, 33]. Some of the 37 patients presented in this 
study have been previously reported [9, 13, 14, 21, 34]. The current study was approved by the 
institutional review board (Ethics Committee Approval no. EC14-011-1).
3. Results
The results summarizing the intraoral involvement in 37 patients are shown in Table 1. All 
37 patients described DG lesions including erythema, erosions, ulcerations, and epithelial 
desquamation (Figures 1–4). The oral lesions were confined to gingiva in 70.3% of patients. In 
a small number of patients, ulcers and erosions were also observed in the buccal mucosa, soft 
palate or tongue (Figures 5–7). Table 2 summarizes the diagnostic pattern in the 37 patients. 
Diagnosis delays of more than 6 months were experienced by 30.8% of the PV patients 
and 54.2% of the MMP patients. 16.7% of patients with MMP were delayed for more than 
12 months from onset to diagnosis. The results summarizing the characteristics of the biopsy 
Site MMP (n = 24) PV (n = 13) Total (n = 37)
Gingiva only 17 (70.8%) 9 (69.2%) 26 (70.3%)
Gingiva + buccal mucosa + tongue 1 (4.2%) 2 (15.4%) 3 (8.1%)
Gingiva + buccal mucosa + soft palate 0 (0%) 1 (7.7%) 1 (2.7%)
Gingiva + buccal mucosa 2 (8.3%) 1 (7.7%) 3 (8.1%)
Gingiva + soft palate 3 (12.5%) 0 (0%) 3 (8.1%)
Gingiva + tongue 1 (4.2%) 0 (0%) 1 (2.7%)
Table 1. Intraoral site involvement in 37 patients.
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findings in these 37 patients are shown in Table 3. Subepithelial separation was observed in 
the H&E-stained section in 20 patients with MMP (Figure 8). Three MMP samples showed 
nonspecific inflammation, and one MMP sample was nondiagnostic because of a total lack 
Figure 1. Desquamative gingivitis associated with mucous membrane pemphigoid. Diffuse erythematous lesions on 
the gingiva.
Figure 2. Desquamative gingivitis associated with pemphigus vulgaris. Patchy erythematous lesions were found on the 
gingiva.
Figure 3. Pseudomembrane-covered erosion of the gingiva associated with mucous membrane pemphigoid.
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of the epithelium in the H&E-stained section. In contrast, acantholysis and a suprabasilar 
separation in the epithelium were observed in the H&E-stained section in all 13 PV patients 
(Figure 9). In the DIF testing, all 37 samples showed positive staining at the BMZ (MMP 
Figure 10) or at the intercellular space (PV Figure 11).
Figure 4. Localized erosions of the gingiva associated with pemphigus vulgaris.
Figure 5. Pseudomembrane-covered erosion of the buccal mucosa associated with mucous membrane pemphigoid.
Figure 6. Localized erosions of the palatal mucosa associated with pemphigus vulgaris.
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After a diagnosis of MMP or PV, patients were advised to confirm the presence or absence of 
extraoral lesions by a dermatologist, otorhinolaryngologist, and ophthalmologist. Eleven (eight 
patients with MMP and three patients with PV) of the 37 patients (29.7%) confirmed the pres-
ence of extraoral lesions. The sites where clinical involvement was found were skin (5 patients), 
upper airway (10 patients), and eye (2 patients). Multiple extraoral mucosal involvements were 
Diagnostic delay Diagnosis
MMP (n = 24) PV (n = 13) Total (n = 37)
≤6 months 11 (45.8%) 9 (69.2%) 20 (54.1%)
7–12 months 9 (37.5%) 4 (30.8%) 13 (35.1%)
>12 months 4 (16.7%) 0 (0%) 4 (10.8%)
Table 2. Diagnostic pattern in 37 patients.
MMP (n = 24) PV (n = 13)
Histopathology
Subepithelial separation 20 0






*A linear BMZ deposition of varying combinations of IgG, IgA, fibrinorgen and complement C3.
**An epithelial intercellular deposition of IgG and complement C3.
Table 3. Biopsy findings in 37 patients.
Figure 7. Desquamative lesion of the tongue associated with pemphigus vulgaris.
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found in four patients with MMP and two patients with PV. All patients with extraoral involve-
ment were managed by medical specialists with systemic treatment with or without hospital-
ization (Figure 12a and b). Patients with exclusively oral lesions were managed at the authors’ 
Figure 8. Hematoxylin-eosin-stained section of mucous membrane pemphigoid. A subepithelial separation was found.
Figure 9. Hematoxylin-eosin-stained section of pemphigus vulgaris. Acantholysis and a suprabasilar separation in the 
epithelium were observed.
Figure 10. Direct immunofluorescence of the mucous membrane pemphigoid. A linear deposition of IgG at the basement 
membrane zone was recognized.
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hospital using a topical corticosteroid combined with effective plaque control. Patients were 
carefully monitored at 2–3 week intervals, and complete remission or minimalization of symp-
toms was achieved (Figure 13a and b).
Figure 12. (a) Desquamative gingivitis associated with pemphigus vulgaris. Localized erosion was observed on the 
palatal mucosa. Lesions were also found on the skin and upper airway. (b) Treatment response. The patient was managed 
by dermatologists with systemic treatment with hospitalization.
Figure 13. (a) Desquamative gingivitis associated with mucous membrane pemphigoid. (b) Treatment response. 
Desquamative gingivitis was successfully managed using a topical corticosteroid combined with effective plaque control.
Figure 11. Direct immunofluorescence of pemphigus vulgaris. An intercellular deposition of IgG was evident.
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4. Discussion
The results of this study indicate that DG is an early sign of autoimmune bullous diseases 
such as MMP or PV. Although multiple oral sites were affected in some patients, 70.3% of the 
oral lesions were confined only to the gingiva, and DG was the only manifestation of the dis-
eases. Data from this study indicate 70.8% of MMP patients had oral lesions confined only to 
the gingiva. This figure agrees with other reports [8, 25]. In contrast, in the present study, the 
frequency of oral lesions limited to the gingiva in PV patients is higher (69.2%) than previous 
reports (3–30%) [17–19, 25, 35]. The oral lesions of PV are usually multiple, typically in the 
buccal mucosa and soft palate [17, 18]. This disparity may be due to the selected bias due to 
an author’s speciality (periodontist), as the patients may have been presenting for treatment 
of gingival lesions. Another limitation is that the number of PV cases is limited.
Nearly half (45.9%) of the patients in this study had experienced diagnostic delays longer than 
6 months, indicating that early diagnosis of autoimmune bullous diseases in the oral cavity was 
still difficult. According to the survey of Sirois et al. [19] diagnostic delays greater than 6 months 
were common in oral PV, but 100% of cutaneous PV patients were correctly diagnosed within 
6 months. Mobini et al. [36] reported that the mean period from onset of the disease until diag-
nosis was 7.57 months in patients with MMP. In this study, diagnosis was delayed more than 
1 year for 16.7% of the MMP patients. This may be related to the characteristics of MMP. The 
initial symptoms of MMP often tend to undergo repeated episodes of onset and remission, 
and spontaneous remission was also observed in a few MMP patients. Furthermore, obtain-
ing diagnostic biopsies from MMP patients is technically challenging. An inadequate surgical 
technique or surgical site selection, or improper tissue handling may easily lead to the loss of 
the gingival epithelium [25, 34, 37]. Four of the patients diagnosed with MMP at the author’s 
clinic were previously biopsied at other facilities, but diagnosis was not rendered. This may be 
because the intact epithelium was not retained in those specimens. To avoid this problem, the 
authors reported a stab-and-roll biopsy technique designed to maintain the gingival epithe-
lium for patients with DG [25, 34]. In this technique, more than 90% of biopsies were obtained 
exhibiting successful retention of intact epithelium, and all biopsies offered diagnostic support 
[34]. This biopsy technique may facilitate early diagnosis and treatment of diseases causing DG.
To establish a correct diagnosis of DG-associated diseases, conventional microscopic exami-
nation and DIF testing are essential. In particular, DIF testing is the gold standard used to 
diagnose autoimmune bullous diseases and is required for a definitive diagnosis [25, 33, 38]. In 
this study, all 37 autoimmune bullous diseases showed positive DIF staining. In H&E findings, 
acantholysis and a suprabasilar separation in the epithelium was observed in all 13 patients 
with PV. In contrast, a subepithelial separation was observed in 20 patients with MMP (83.3%). 
Since epithelial acantholysis is quite distinctive, it may be possible that correct diagnosis to be 
rendered based on H&E findings alone [38]. In contrast, the subepithelial separation, which is 
a characteristic of MMP patients, is a nondiagnostic finding as it is also found in other vesicu-
lobullous diseases. Therefore, the international expert consensus on MMP does not consider 
results from conventional microscopic studies as an absolute criterion for the diagnosis [2].
In this study, extraoral lesions were confirmed in 11 of the 37 cases (29.7%) at the time of 
diagnosis. Since the oral cavity is the site of most problematic lesions, the patients came to 
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the author’s hospital first. Concomitant extraoral lesions were more common in MMP, and 
the patients tended to be affected in multiple mucosal sites or skin. Multiple target antigens 
of MMP were identified in BMZ components by the appearance of circulating autoantibod-
ies in the patients’ serum [2–5]. Therefore, it is currently believed that MMP is not a single 
entity but has distinct clinical subsets. For example, some MMP patients have involvement 
limited to the conjunctiva. They are referred to as having ocular cicatricial pemphigoid [39, 
40]. Similarly, Mobini et al. [36] proposed that the MMP lesions confined only to the oral 
cavity are called “oral pemphigoid.” In these clinical subsets, other mucous membranes and/
or skin are not involved at long-term follow-up [4, 36, 41]. Di Zenzo et al. [42] pointed out in 
their review that it is important to know whether the exclusive oral lesion is only a stage of the 
course of MMP or if it represents the phenotype of a distinct clinical entity. In some long-term 
studies, MMP patients with exclusively oral lesions show that lesions do not develop in other 
mucous membranes and/or skin during follow-up [4, 36, 41]. In contrast, other studies indi-
cate that MMP patients with initial oral lesions have a risk of developing ocular involvement 
with a calculated incidence rate from 0.03 to 0.05 persons per year [28, 29]. Several authorities 
suggest that early diagnosis of ocular MMP lesions is essential to successful management yet 
early signs of MMP may not be readily evident to other healthcare workers. Consequently, it 
may be advisable to refer any MMP patient to an ophthalmologist for immediate and long-
term follow-up. Although there is a possibility that the clinical subset of MMP is classified 
based on the antibody profiles in their serum [3], at present, there is no known correlation 
between antigen-specific autoantibodies and the prognosis of disease [2].
PV frequently begins with oral lesions and later progresses to skin lesions [19]. Patients with 
PV with exclusively oral lesions should be followed closely and referred to other experts 
immediately if they develop signs or symptoms of lesions elsewhere on the body. Although 
the necessity of systemic therapy is decided with reference to the circulating anti-Dsg anti-
body titer in some cases, the therapeutic approach to PV is largely based on expert opinion 
rather than empirical evidence [43–46]. The monitoring of PV disease activity is mainly based 
on clinical findings at the present moment [43, 45, 46]. In any case, PV limited to oral cavity 
should be followed for a long period of time and perhaps indefinitely.
5. Conclusion
DG is an early sign of autoimmune bullous diseases such as MMP or PV in the oral cavity. In 
this study, about 70% of the oral lesions are confined to the gingiva, and DG was the only mani-
festation of the diseases. To establish a correct diagnosis of DG caused by autoimmune bullous 
diseases, conventional microscopic examination and DIF testing are essential. In particular, DIF 
testing is the gold standard used to diagnose of MMP or PV. Since some lesions remain limited 
to the oral cavity for a long period of time, patients diagnosed with MMP or PV should be closely 
followed because they must be immediately referred to other experts when they develop lesions 
on parts of their body other than the oral cavity. The oral healthcare provider should collaborate 
with other healthcare experts including dermatologists, ophthalmologists, and otolaryngolo-
gists to evaluate and manage patients with autoimmune bullous diseases in the oral cavity.
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